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Abstract 
Background: Severe malaria is a leading cause of morbidity and mortality in under-fives in sub-Saharan Africa. 
Recently quinine has been replaced by artesunate as the first-line drug in the treatment of severe malaria in Cam-
eroon. Artesunate has been shown to be cost-effective in African children, but whether these findings are transferable 
to Cameroonian children remains to be explored.
Objectives: To conduct a cost-analysis of four different regimens used in the treatment from the perspective of the 
healthcare payer.
Methods: An economic evaluation alongside a randomized comparative study was conducted in children aged 
3 months to 15 years, admitted at the Ebolowa Regional Hospital with severe malaria due to Plasmodium falciparum. 
Patients were randomized to receive one of the four treatment alternatives. Group 1 (ARTES) received parenteral 
artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily; Group 2 (QLD) received a loading dose of quinine base 
at 16.6 mg/kg followed 8 h later by an 8-hourly maintenance dose of 8.3 mg/kg quinine base; Group 3 (QNLD3) 
received 8.3 mg/kg quinine base every 8 h, and Group 4 (QNLD2) received 12.5 mg/kg quinine base every 12 h. The 
main outcome measure for effectiveness of treatment was the parasite reduction rate. Based on a healthcare perspec-
tive, an evaluation of direct medical costs was done, including costs of anti-malarials, nursing care materials, adjuvant 
treatment, laboratory investigations, hospitalisation and professional fees. Guided by a cost minimalization approach, 
the relative costs of these treatment alternatives was compared and reported.
Results: Overall cost was higher for ARTES group at $65.14 (95% CI $57.68–72.60) than for quinine groups ($52.49–
$62.40), but the difference was not statistically significant. Cost of the anti-malarial drug was significantly higher for 
artesunate-treated patients than for quinine-treated patients, whereas cost of hospitalization was significantly lower 
for artesunate-treated patients than for quinine-treated patients. Incremental analysis of ARTES against QLD as a base-
line resulted in an ICER of $46.8/PRR24 and suggests ARTES as the most cost effective of all four treatment options.
Conclusion: Artesunate is a cost effective malaria treatment option relative to quinine alternatives with the lowest 
incremental cost per unit of effectiveness.
Trial registration clinicaltrials.gov identifier: NCT02563704. Registered 19 September 2015, retrospectively registered
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Background
The deadline for the Millennium Development goals has 
come and gone but not all developing countries have 
achieved the targeted reductions in key health indices 
and improvements in human development; for exam-
ple, the 4th millennium development goal was to reduce 
child mortality by two-thirds between 1990 and 2015 [1]. 
In 1990, the Cameroonian under-five mortality was 138 
death per 1000 live births, but decreased to 88 deaths 
per 1000 live births in 2015, which is above the 46 deaths 
per 1000 live births that were targeted [2]. The recently 
adopted United Nations Sustainable Development goals, 
specifically targets a further reduction of under-5-mor-
tality to 25 deaths per 1000 live births by 2030. Cam-
eroon is thus amongst the countries with least progress 
and substantial changes are needed to reach the goal of 
25 deaths per 1000 live births by 2030 [3].
Malaria is one of the most common childhood diseases 
and a major obstacle for economic and human develop-
ment in sub-Saharan Africa. It is a leading cause of child 
mortality and constitutes the main cause of inpatient 
admission in paediatric wards. In 2011 in Cameroon, 
malaria was responsible for 24% of total deaths, 40–45% 
of medical consultations and 30% of hospital admissions 
in under-fives [4]. Effective case management of severe 
malaria can help reduce this mortality; however, a pos-
sible barrier to accessing appropriate case management is 
the cost of treatment [5].
The World Health Organisation (WHO) currently rec-
ommends parenteral artesunate as the drug of choice in 
the treatment of severe malaria in children and quinine 
as the second line drug [6, 7]. This recommendation is 
based on two key studies: SEAQUAMAT (South-East 
Asian Quinine Artesunate Malaria Trial) that was con-
ducted in four South-East Asian countries with over 1461 
patients (including 202 children) [8] and AQUAMAT 
(Artesunate versus Quinine in the treatment of severe 
malaria in African children) that was undertaken in 11 
centres in 9 African countries and conducted with over 
5400 children [9]. These studies revealed a relative reduc-
tion of mortality of 34.7 and 22.5% respectively in artesu-
nate recipients. The costs of inpatient care of children 
with severe malaria were assessed in four of the 11 sites 
included in the AQUAMAT study. Overall, treatment 
with quinine was evaluated at US$ 63.5 and that with 
artesunate was evaluated at US$ 66.5 [10].
A review of policy by the Cameroon National Malaria 
Control Programme in 2013 recommended paren-
teral artesunate as first-line drug for treatment of severe 
malaria. The policy also recommended two regimens 
of quinine: a loading dose regimen of 16.6  mg/kg body 
weight quinine base (QB) as loading dose followed 8  h 
later by an 8-hourly maintenance dose of 8.3  mg/kg 
body weight; and a non-loading dose regimen of 8.3 mg/
kg body weight QB every 8  h [11]. Some health institu-
tions in Cameroon also use a twice daily administration 
of quinine at a dose of 12.5 mg/kg body weight QB every 
12 h because of its feasibility based on limited personnel 
and 12 hourly nursing rotation. Although policy has been 
established, cost may still be a major factor limiting access 
to treatment for many patients. Monthly malaria expen-
ditures as a proportion of monthly non-food household 
expenditures could be as high as 7.1 and 5.0% for rural 
and urban dwellers respectively [12]. This high economic 
burden of malaria can result in catastrophic costs and 
thus prevent people from seeking care when needed.
Cameroon is a lower middle-income country with 
a per capita income of $1407 and total health spend-
ing per capita of $59 per annum [13]. Although govern-
ment spending has increased over a decade from $31 
in 2002 to $59 in 2014, households continue to bear the 
greater part of the financial burden of healthcare. This 
is in spite of the fact that government provides free and 
heavily subsidised healthcare services covering treat-
ment of malaria for children below 5 years of age. There 
are community based health insurance schemes serving 
various segments of the population but there is yet to 
evolve a common national strategy for Universal Health 
Insurance in Cameroon. Without the financial protec-
tion of a pre-paid health financing system, patients have 
to pay hospital charges for support services and purchase 
pharmaceuticals and consumables for the treatment of 
malaria. Therefore, more than 70% of the total health 
spending is still in the form of inequitable OOPs to sup-
plement services in public facilities or to obtain care from 
the parallel private sector [14]. These funds come from 
financially constrained individuals and households. Cost 
is, therefore, a key issue in determining who can access 
appropriate and qualitative treatment of life threatening 
severe malaria.
Another factor determining the choice of anti-malaria 
treatment prescribed to patients is evidence-based 
knowledge on relative cost-effectiveness of treatment 
alternatives available to physicians and other key deci-
sion-makers in the health system. The healthcare mar-
ket has unique features when compared to the market 
for normal goods where consumers are decision makers 
on choice and quantity of goods consumed. The agency 
relationship is a unique feature of healthcare in which 
the healthcare provider (supplier) rather than the patient 
(consumer) is the decision maker for choice of treatment 
alternative and indirectly determines the cost of health 
services consumed by patients. Such decision making 
by physicians is best supported by information from a 
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structured comparative analysis or economic evaluation 
of costs and benefits of treatment alternatives.
Economic evaluations are increasingly being conducted 
alongside randomized comparative trials (RCT) as a 
means of providing researchers with individual patient 
data used to estimate cost effectiveness. Thus, a RCT of 
four different treatment alternatives for severe malaria 
was conducted—parenteral artesunate with three quinine 
regimens—using parasite reduction rate 24 h after onset 
of treatment (PRR24) as the main outcome measure and 
economic data collected from a healthcare perspective; 
in a hospital located in a malaria endemic geographi-
cal region of Cameroon: The Ebolowa Regional Hospital 
(ERH). Such an analysis of the costs and effectiveness of 
various treatment options for severe malaria will provide 
information underpinning government policymaking on 




This study was conducted in the paediatric unit of ERH, 
which is the referral hospital in Ebolowa region of south-
ern Cameroon. It has a total capacity of 158 beds for an 
estimated population of 120,000 inhabitants. The paedi-
atric unit itself has a capacity of 28 beds and is headed by 
a paediatrician assisted by a physician intern, supported 
by ten nurses working in teams of 2–3 per shift. There are 
prescribed fees according to a government tariff for con-
sultation, laboratory investigations and pharmaceuticals. 
These fees are payable in public health facilities including 
Ebolowa General Hospital where this study was carried 
out. The Ebolowa health district in which the hospital is 
located is a heavily malaria-endemic area characterized 
by a stable, perennial malaria transmission. Although the 
Ebolowa region of Cameroon is the headquarters of the 
South Region of Cameroon, it is less affluent than major 
cities, such as Douala and Yaoundé, the economic and 
political capitals respectively of Cameroon. The people 
are mainly farmers and small-scale traders with limited 
resources who will need to make rational decisions about 
utilization of healthcare facilities and treatment options.
Study design
This economic evaluation was designed as a randomized 
comparative study of four treatment regimens, carried 
out from September 1st 2013 to March 31st 2014. Eco-
nomic data was collected alongside clinical effectiveness 
data from each patient using a questionnaire adminis-
tered by trained researchers. The result of the compara-
tive effectiveness of the treatment alternatives has been 
previously reported and published [15].
Study population
A consecutive sampling of all children admitted for 
severe malaria, who fulfilled to the inclusion criteria in 
the paediatric unit of the Ebolowa Regional Hospital dur-
ing the study period was done. Inclusion criteria for the 
study were:
  • Children with malaria parasitaemia positive for Plas-
modium falciparum and confirmed on microscopy.
  • Children aged 3 months to 15 years old irrespective 
of sex.
  • Children presenting with one or more signs of severe 
malaria according to the 2013 Cameroon National 
Malaria Control Programme adopted criteria 
(impaired consciousness, abnormal behaviour, con-
vulsions, prostration, persistent vomiting, jaundice, 
hyperthermia (temperature ≥40  °C), acute respira-
tory distress, clinical acidosis, haemoglobinuria, car-
diovascular shock, dehydration, abnormal bleeding, 
severe anaemia, renal impairment, hypoglycaemia 
and hyperparasitaemia).
  • Other differential diagnosis of the presenting symp-
toms was excluded.
  • Parents gave a written informed consent.
Excluded from the study were children who have 
reported prior side effects to artesunate or quinine 
administration, severely malnourished children, and 
those who had a concomitant infection.
Randomization and masking
Eligible patients were randomly assigned to receive 
either parenteral artesunate or one of the three quinine 
regimens. Using Kendall and Babington Smith random 
number table [16], an assistant not involved in the study 
performed the randomisation in advance in blocks of 
20 composed of five of each regimen. Treatment allo-
cations were placed in numbered opaque sealed enve-
lopes to which the investigator was blinded till a patient 
was admitted. On admission, each patient was allocated 
an envelope corresponding to his unique identification 
number.
Description of treatment alternatives and outcome 
measure
WHO policy on the case management of severe malaria 
recommends parenteral artesunate in prescribed doses 
as treatment of first choice; and where that is not avail-
able quinine can be used [6, 7]. Therefore, a comparison 
of parenteral artesunate with quinine in three differ-
ent treatment regimens was chosen. The four treatment 
alternatives were:
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1. Group 1 (ARTES) where patients received parenteral 
artesunate at 2.4  mg/kg at H0, H12, H24 for at least 
24  h and then once daily till the patient could take 
oral drugs.
2. Group 2 (QLD) where patients received a loading 
dose of quinine base at 16.6 mg/kg followed 8 h later 
by an 8-hourly maintenance dose of 8.3  mg/kg qui-
nine base for at least 24  h and then till the patient 
could take oral drugs.
3. Group 3 (QNLD3) where patients received 8.3 mg/kg 
quinine base every 8 h for at least 24 h and then till 
the patient could take oral drugs.
4. Group 4 (QNLD2) where patients received 12.5 mg/
kg quinine base every 12 h for at least 24 h and then 
till the patient could take oral drugs.
Each patient was assessed at admission and admit-
ted by the physician who developed a treatment plan. A 
consultant paediatrician would also review and approve 
the treatment plan including adjuvant treatment. Each 
dose of anti-malarial was administered by the nurse-
on-duty and patient signs, symptoms and laboratory 
parameters were assessed at base case and daily until 
discharge. For each treatment regimen, parenteral treat-
ment was relayed with an artemisinin-based combination 
(artemether–amodiaquine or artemether–lumefantrine) 
as soon as he could take oral treatment before being 
discharged from the hospital. The procedure for dilu-
tion and administration of the drugs and monitoring for 
clinical side-effects have been described in a previously 
published paper [15]. Malaria thick films were conducted 
on each patient at base case on admission and daily until 
discharge.
The outcome measure for an economic evaluation can 
be expressed in natural units or a generic measure, such 
as quality-adjusted life year (QALY) or disability-adjusted 
life year (DALY), based on expressed health preferences 
or in monetary units. For this study the primary out-
come measure adopted for all treatment alternatives was 
in natural units—parasite reduction rate 24 h after onset 
of treatment (PRR24). A generic measure was not used 
because of the lack of locally generated preference based 
measures.
Identification and measurement of costs
The study perspective is the viewpoint from which the 
costs and consequences of an intervention are evalu-
ated. Although the societal perspective is the broadest 
perspective for an economic evaluation, costing for this 
study was conducted from the healthcare payer’s per-
spective. It is believed that this perspective covers the 
anticipated costs from treatment of severe malaria. Addi-
tionally, the lack of reliable data on productivity costs 
and market wage rates in developing countries made this 
the logical choice. The estimation covered direct medical 
costs attributable to each treatment alternative for severe 
malaria; namely the costs of anti-malarial drugs, nursing 
care materials, adjuvant treatment, laboratory investiga-
tions, hospitalisation and professional fees. Time and 
travel costs were excluded.
The time horizon refers to the length of time, over 
which costs and consequences are being evaluated. A 
suitable time horizon should be long enough to capture 
all associated costs and benefits of the treatment alterna-
tives. The time horizon for this economic evaluation was 
over the course of the disease rather than the lifetime of 
the patient hence costs were identified, established and 
updated continuously from presentation at the facility, 
over the period of admission and ended at discharge. It 
was stopped at discharge because costs attributable to 
malaria or the treatment alternatives are negligible after 
discharge. The International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) guidelines were 
followed in the identification and measurement of all 
costs [17].
Valuation of costs
The cost headings identified were in six categories as 
detailed in Table 1. In terms of valuation, the cost of anti-
malarial drugs was determined using the price indicator 
guide obtained from the hospital pharmacy. If a drug 
was bought from a commercial pharmacy in town, a 
weighted price from a survey of sellers’ prices was used 
in the estimation. Unit prices of all other resources used 
in the analysis were obtained from two sources: the price/
fee schedule of the Ebolowa Regional Hospital and com-
mercial costs such as over-the-counter medications were 
determined by imputation from a survey of pharmaceu-
tical vendors. Professional fees for doctor consultation 
and nursing time were determined by imputation from 
Cameroon Health sector salary scale. Laboratory tests 
included a suite of 3–15 thick blood films per patient and 
the cost of all these blood films was included in the price 
estimation even though the patient was billed for only 
one film. Total cost of hospitalization was obtained by 
multiplying the cost per inpatient day with the length of 
stay in the hospital.
Economic studies of this nature typically consider costs 
rather than charges to reflect the opportunity cost of the 
alternative treatment option forgone. In many developing 
countries hospital charges may deviate from actual costs 
because of government subsidies. There was no means 
of converting these hospital charges and market prices 
and there is not an applicable cost-charge ratio. The 
pragmatic approach for this study was, therefore, to use 
the market prices as proxy for the opportunity cost. For 
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same reasons a cost-to-charge ratio was not applied nei-
ther did we attempt to assess the impact of government 
subsidies on the hospital prices. There was no objective 
means of adjusting the prices based on these considera-
tions and the difference in cost might not bias the study. 
Fixed costs such as hospital capital and overhead costs 
were considered to be costs common to all treatment 
alternatives. Additionally, such detailed costing data was 
not available at the Ebolowa District Hospital. Fixed costs 
were, therefore, not included in the analysis even though 
this could be a possible source of bias. All costs were 
initially expressed in CFA Francs in the base case analy-
sis and then converted to US dollars (2016) in the final 
analysis. Although both clinical and economic data was 
collected, the paper on the clinical effectiveness was the 
more pragmatic and first to be published. It has taken 
some time to find requisite skills to develop and write 
the economic evaluation hence the time lag between data 
collection and publication. Since all costs were collected 
within a 12-month time frame, discounting of costs was 
not necessary.
Cost effectiveness analysis
A cost effectiveness analysis (CEA) was chosen because 
it provides a framework to do a comparative analysis of 
the relative costs and effectiveness of all four alternative 
treatments. As a tool of economic analysis, it enables us 
determine the total cost of each alternative, the variance 
between the total cost and the separate cost headings and 
compare this with the effectiveness of each treatment 
alternative. Within this analysis, it was also possible to 
apply tests of significance to further confirm that vari-
ances in costs are not due to random differences. Finally, 
the costs and benefits of each alternative were compared 
using the mean cost per patient as a measure of cost and 
the parasite reduction in 24  h (PRR24) as a measure of 
effectiveness. The results are presented as cost per PRR24 
as a measure of cost-effectiveness.
The incremental cost-effectiveness ratio is (ICER) is the 
additional cost that a decision maker has to bear in order 
to achieve an additional unit of effectiveness—in this case 
the cost of each additional measure of parasite reduction. 
The ICERs was calculated for all treatment options and 
the decision rules were applied. As there are no locally 
specified protocols for reporting economic evaluations, 
the Consolidated Health Economic Evaluation Reporting 
Standards based on the ISPOR Task Force Report of 2015 
were followed [18].
Statistical analysis
Data were coded as variables, introduced in Epi Info™ 
version 3.5.3 software and double-checked before analy-
sis. In cases of patients with incomplete cost data, the 
missing information was estimated by imputation. 
Numerical variables were summarised into means and 
standard deviations. Categorical variables were summa-
rised in cross-tables and Chi square test was used to com-
pare the different proportions. A two-group comparison 
(ARTES/QLD, ARTES/QNLD3 and ARTES/QNLD2) of 
the different costs was done and Student t test was used 
to compare the mean costs in the different groups. Analy-
sis was done by intention-to-treat and a p value less than 
0.05 was considered statistically significant.
Both mean and incremental analysis of the costs was 
conducted. Mean costs were calculated for all cost head-
ings while incremental analysis was carried out for the 
total cost of each treatment alternative. The median costs 
and confidence intervals are also reported. Although 
costs and effect of malaria fall within a very short time 
frame and its treatment pathway is limited, a simple 
probabilistic modelling in form of a decision tree was 
done, as well as calculations of the probabilities of each 
pathway, expected cost and expected effect. All treatment 
cycles ended in less than a month and therefore there was 
no justification for a Markov model.
Results
A total of 281 children admitted for severe malaria at 
ERH were assessed for eligibility. Following diligent scru-
tiny of the inclusion and exclusion criteria, 118 patients 
were eligible and enrolled in the study. A total of 30 sub-
jects were randomized to the ARTES (Artesunate) group, 
28 subjects to QLD group, 30 subjects to QNLD3 group, 
and 30 subjects to QNLD2 group (Fig.  1). Two patients 
died, one in the ARTES group 4  h after onset of treat-
ment and one in the QNLD2 group 18  h after onset of 
Table 1 Overall cost per PRR24 and patient cost per PRR24
ARTES QLD QNLD3 QNLD2
PRR24 (%) 92 74.8 66.5 71.7
Overall cost 1954.08 1747.12 1991.68 1807.14
Overall cost/PRR24 $21.24 $23.34 $29.95 $25.20
Mean cost per patient 65.14 (57.68–72.60) 62.40 (52.67–72.13) 66.40 (57.03–75.77) 60.23 (51.55–68.91)
Mean cost per patient/PRR24 (95% CI) $0.71 (0.63–0.79) $0.83 (0.7–0.96) $0.99 (0.85–1.13) $0.85 (0.73–0.97)
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treatment, representing a mortality rate of 3.3% in each 
group. Consequently, data was analysed by intention-to-
treat. The full analysis of resources used under each of 
the six cost headings by specification, measurement, val-
uation and source of data is detailed in Table 1.
Clinical effectiveness
The results of the clinical effectiveness of each treat-
ment group measured in PRR24, is presented in Table  1 
and have been previously reported in another publica-
tion [15]. Results show that ARTES had statistically sig-
nificantly higher effectiveness than any of the quinine 
treatment alternatives. ARTES recorded parasitological 
effectiveness of 92% followed by QLD with 74.8% and 
QNLD2 with 71.7%. The lowest parasitological effective-
ness was recorded by QNLD3 with a PRR24 of 66.5%. In 
terms of secondary clinical outcomes such as fever clear-
ance time and parasite clearance time were significantly 
shorter for artesunate-treated patients than for quinine-
treated patients.
Cost of antimalarial treatment
Two anti-malarial drugs—artesunate and quinine—were 
used in the study; details of specifications, quantities and 
costs are presented in Tables 2 and 3. During the study 
period, 93 ampoules of artesunate were bought against 
48 ampoules of quinine for QLD group, 52 ampoules of 
quinine for QNLD3 group and 56 ampoules of quinine 
for QNLD2 group. The total cost of anti-malarial drug 
in ARTES group was 231.57 USD with a mean cost per 
patient of 7.72 USD which was significantly higher than 
that of the quinine groups (p < 0.001, see Tables 2, 5). In 
terms of proportion, anti-malarial represented 11.85% 
of total cost of treatment in the ARTES group compared 
to 3.87, 4.22 and 5.0% in the QLD, QNLD3 and QNLD2 
groups, respectively; or an average of 4.36% in the qui-
nine groups.
Cost of nursing care materials
The cost of nursing care materials in all patients ranged 
from 2.92 to 4.30 USD with a mean of 3.46 USD. The 
average cost of nursing care materials per patient was 
similar for the four groups (Tables 4, 5). Cost of nursing 
care materials as a proportion of total cost of treatment 
ranged from 5.3% in ARTES to 6.52% in the QNLD2 
group.
Cost of adjuvant treatment
Mean cost of adjuvant treatment was 19.03 USD with a 
range of 3.52–51.31 USD. This cost heading represented 
31.66–32.65% of the total cost of treatment in the various 
treatment alternatives. The total cost of adjuvant treat-
ment was highest in the ARTES group with 619.24 USD 
but the difference with the other groups was not statisti-
cally significant (see Tables 5, 6).
Artesunate-treated patients used less dextrose solu-
tions than quinine-treated patients (Table 6). The trans-
fusion related costs in each group were also isolated. 
There were more transfusions in the ARTES group (15 
compared to 8 in QNLD2) due to randomization, result-
ing in higher adjuvant costs than in any of the quinine 
groups. The additional transfusion costs were 383.10 
USD in ARTES compared to 204.32 USD in QNLD2. 
When transfusion costs are deducted from the total cost 
of adjuvant treatment, QNLD3 has the highest adjuvant 
cost while ARTES has the lowest cost per patient (see 
Tables 6, 7).
Cost of laboratory investigations
Quantities and cost of laboratory investigations varied 
widely among the groups. Overall, costs of laboratory 
investigations ranged from 9.04 to 55.36 USD with a mean 
23.56 USD. The mean cost per patient for laboratory inves-
tigations was lower for patients in the ARTES group than 
for those in the quinine groups but the difference was not 
statistically significant (Tables  5, 8). In the study, a total 
of 750 thick blood smears was done for the entire patient 
population (ranging 3–15/per patient). The overall cost of 
laboratory investigations was higher in the non-loading 
quinine treatments than ARTES and QLD. The number 
of thick blood films and total cost of tests for malaria was 
highest in the non-loading quinine treatments with 501.12 
and 475.20 USD respectively. The ARTES group also 
recorded higher quantities of tests for packed cell volume, 
full blood count and blood group/rhesus typing.
Cost of hospitalization
Duration of hospitalisation ranged from 0 to 5  days. 
The mean number of days on admission was shorter in 
the ARTES group followed by the QNLD2 group, QLD 
group and finally QNLD3 group (Table 9). Consequently, 
Fig. 1 Study profile
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patients in the ARTES group spent less for hospitaliza-
tion as compared to those in the quinine groups. The 
highest total cost of hospitalization of 192.5 USD and 
mean cost per patient of 6.425 USD was recorded in the 
QNLD3 group. This difference was statistically significant 
(Table 9).
Table 2 Resource use by category, specification, measure, source and cost in CFA and USD
a Based on a currency conversion rate of 60,179CFA to $1 as at 8th January 2016
Resource category Resource specification Unit Unit costs (CFA) Unit cost (USD)a Source of cost
A. Anti-malaria drug Artesunate i/v 60 mg Ampoule of 2 ml 1500 2.49 HPI/commercial survey
Quinine i/v 1500 mg Ampoule of 2 ml 850 1.41 HPI/commercial survey
B. Nursing care materials Cleaning alcohol 1 pack of 50 ml 400 0.66 HPI/commercial survey
Cotton 1 pack of 20 g 325 0.54 HPI
Non-sterile gloves 1 pack of 2 units 100 0.17 HPI
Infusion set 1 unit 175 0.29 HPI
Intravenous catheter 1 unit 400 0.66 HPI
Syringes 1 unit of 10 cc 55 0.09 HPI
C. Laboratory investigation Thick film Cost per test 1300 2.16 HPI
Packed cell volume Cost per test 1550 2.57 HPI
Full blood count Cost per test profile 4000 6.64 HPI
Blood group, rhesus typing Cost per test 2350 3.90 HPI
CSF analysis Cost per test 11,000 18.28 HPI
Chest X-ray Cost per film 5400 8.97 HPI
D. Hospitalisation Admission fees Cost per day 1500 2.49 HPI
E. Professional fees Doctor consultation—GP Cost per consultation 600 1.00 Hospital fee schedule
Doctor consultation—paediatri-
cian
Cost per consultation 2000 3.23 Hospital fee schedule
Nursing care time Cost per day 1500 2.49 Hospital fee schedule
Out-patient consultation Cost per patient 600 1.00 Hospital fee schedule
F. Adjuvant treatment i/v fluids—dextrose Pack of 500 mls 925 1.54 HPI/commercial survey
i/v fluids—electrolytes Pack of 500 mls 90 0.15 HPI/commercial survey
Paracetamol injection Ampoules of 1 g 2520 4.19 HPI/commercial survey
Diazepam injection Ampoules of 10 mg 170 0.28 HPI
Phenobarb injection Ampoules of 200 mg 325 0.54 HPI
Furosemide injection Ampoules of 10 mg 100 0.17 HPI
Transfusion set 1 unit 275 0.46 HPI
Transfusion fees Cost per transfusion 15,000 24.91 HPI
Naso-gastric tube 1 unit 2250 3.74 HPI
Naso-gastric tube posing fee Cost per insertion 2500 4.15 HPI
Syringe 1 unit of 60 ml 3000 9.97 HPI










Number of antimalarial ampoules used 93 48 52 56
Mean number of ampoules per patient 3.1 1.71 1.73 1.87
Cost per ampoule—artesunate ($) 2.49 NA NA NA
Cost per ampoule—quinine ($) NA 1.41 1.41 1.41
Total cost of anti-malaria treatment per group ($) 231.57 67.68 73.32 78.96
Mean cost per patient ($) (95% CI) 7.72 (7.28–8.16) 2.42 (2.07–2.77) 2.44 (2.05–2.83) 2.63 (2.05–3.21)
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Cost of professional fees
Professional fees were calculated based on cost of nurs-
ing care per day, cost of doctor consultation for general 
practitioner (GP) and doctor consultation for paediatri-
cian. The cost of nursing time as well as the total cost of 
professional fees was highest in the QNLD3 with 255.18 
USD or 8.51 USD per patient. The lowest cost of 217.05 
USD or 7.24 USD per patient was recorded in the ARTES 
group (Table 10).
Overall cost per patient for the ARTES group was 65.14 
USD, which was higher than for the any of the quinine 
groups although the difference was not statistically sig-
nificant (see Table  8). Of the quinine groups, total cost 
was lowest in the QNLD2 group and highest in the QLD 
group. With regards to cost headings, the ARTES group 
recorded highest cost of anti-malarial drugs and adju-
vant care materials but lower cost of laboratory investi-
gations, admission and professional fees than the quinine 
groups. Within the quinine groups, the cost of adjuvant 
care, laboratory investigations, admission and profes-
sional fees was highest in the QNLD3 group and lowest 
in the QNLD2 group. The two-by-two comparison of the 
ARTES group with each quinine group showed no statis-
tical significant differences between the groups (Table 5).
Incremental cost effectiveness ratio
The ICER is an estimation of the cost to be paid for an 
extra unit of effectiveness of the more effective but cost-
lier intervention; in this case ARTES. To determine the 
ICER, all four mutually exclusive treatment options 
were first listed in order of increasing cost, revealing 
that QNLD3 was dominated and QNLD2 was extend-
edly dominated and excluded from the analysis. Based 
on decision rules, ARTES was identified as the most cost 
effective treatment option relative to QLD, with an incre-
mental cost of $46.78 per PRR24 (Table 11).
Discussion
The study reveals that ARTES has higher cost ($65.14) 
than any of the quinine treatment options explored 
($52.49–$62.40), but ARTES also has the highest clinical 
effectiveness overall. However, there is no significant dif-
ference in the overall cost of treatment of severe malaria 
with artesunate compared to quinine. This result com-
pares favourably to the mean costs from studies by Lubell 
et al. [10] who recorded $66.5 for ARTES and $63.5 for 
the quinine groups. Since the management of severe 
malaria is mainly hospital-based, the study focused only 
on costs from presentation in hospital until discharge, 
excluding household costs, the collection of which is 
resource-intensive. Studies by Lubell also excluded 
household costs. When individual cost headings are 
considered; significant differences exist in the cost of 
anti-malarials (in favour of quinine) and in the cost of 
hospitalization (in favour of artesunate). Further analysis 
shows that the cost per PRR24 was lower for the artesu-
nate group than for the quinine groups. In all the groups, 
with regards to proportion of total cost, adjuvant care 
and laboratory materials were the major costs incurred 
by patients.
On average, artesunate-treated patients significantly 
spent more for anti-malarials than quinine-treated 
patients with mean cost of $7.72 per patient compared 
to $2.5 in the quinine groups. This observation is simi-
lar to that of Lubell et al. [10], who evaluated cost in the 
AQUAMAT study. They obtained a mean cost of US$ 











Quantity Total cost Quantity Total cost Quantity Total cost Quantity Total cost
Adhesive plaster  
(1 roll)
0.42 30 12.6 28 11.76 30 12.60 30 12.60
Alcohol (50 ml) 0.66 30 19.8 28 18.48 30 19.80 30 19.80
Cotton (1 packet) 0.54 30 16.2 28 15.12 30 16.20 30 16.20
Non sterile gloves  
(1 pair)
0.17 90 15.3 87 14.79 95 16.15 85 14.45
Infusion set (1 unit) 0.29 30 8.7 28 8.12 30 8.70 30 8.70
Intravenous catheter 
G24
0.66 30 19.8 28 18.48 30 19.80 30 19.80
Syringes 10 cc 0.09 123 11.07 118 10.62 129 11.61 124 11.16
Total cost per treat-
ment group
103.47 97.37 104.86 102.71
Mean cost per patient 
in USD (95% CI)
3.45 (3.42–3.47) 3.48 (3.42–3.54) 3.50 (3.40–3.58) 3.42 (3.36–3.48)
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3.3 for artesunate ampoules as compared to US$ 1.3 for 
quinine ampoules. This difference in cost is due to the 
fact that, firstly, artesunate is more expensive than qui-
nine. Secondly, once artesunate has been reconstituted, it 
must be discarded within an hour whereas quinine can 
be conserved for later use. The mean cost per patient for 
quinine ampoules in the QLD group was lower than that 
of the non-loading dose regimens. This difference can be 
explained by the fact that clinical recovery and parasitae-
mia negation were faster in the loading dose group than 
in the non-loading dose groups, thus duration of hospi-
talization was shorter for patients of the QLD group than 
for those of the QNLD3 and QNLD2 groups.
Adjuvant treatment considerably increases the cost of 
severe malaria and constituted 34.1% of the overall cost. 
Considering the average quantities of dextrose solution 
and electrolytes, smaller quantities were used for artesu-
nate-treated patients than for quinine-treated patients. 
This is because dextrose was used to keep the vein pat-
ent for artesunate-treated patients whereas each dose of 











Quantity Total cost Quantity Total cost Quantity Total cost Quantity Total cost
Dextrose solu-
tion (500 ml)
1.53 51 78.03 69 105.57 88 134.64 91 139.23
Electrolytes 
(500 ml)
0.15 101 15.15 102 15.53 107 16.05 112 16.80
Paracetamol 
injection (2 ml)
4.18 27 112.86 25 104.50 28 117.04 26 108.68
Diazepam injec-
tion (2 ml)
0.28 6 1.68 6 1.68 11 3.08 8 2.24
Phenobarbital 
injection (2 ml)
0.54 5 2.70 2 1.08 4 2.16 3 1.62
Furosemide 
injection (2 ml)
0.17 15 2.55 12 2.04 10 1.70 8 1.36
Transfusion set (1 
unit)
0.46 15 6.90 12 5.52 10 4.60 8 3.68
Transfusion fees 
per pint of 
blood
24.91 15 373.65 12 298.92 10 249.10 8 199.28




4.15 2 8.30 2 8.30 3 12.45 2 8.30
Syringe 60 cc, 
mean
2.49 2 9.96 2 9.96 3 14.94 2 9.96
Total cost per 
group
619.24 560.56 566.95 498.61




9.40 (7.71–33.41) 9.46 (7.99–33.26) 9.60 (8.25–29.07)
Table 7 Transfusion related costs by the treatment groups (furosemide, transfusion set and transfusion fees)










TC (+ Tx costs) per group 619.24 560.56 566.95 498.61 ARTES has highest adjuvant care cost
Tx related costs 383.10 306.48 255.40 204.32 ARTES has highest transfusion cost
TC (− Tx costs) 236.14 254.08 311.55 294.29
AC (+ Tx costs) 20.64 20.02 18.90 16.62 ARTES has lowest and QNLD3 has highest cost without Tx
AC (− Tx costs) 7.87 9.07 10.39 9.81
Page 11 of 15Maka et al. Malar J  (2016) 15:587 













Quantity Cost in USD Quantity Cost in USD Quantity Cost in USD Quantity Cost in USD
Thick blood 
films
2.16 140 302.40 158 341.28 232 501.12 220 475.2
Packed cell 
volume
2.57 38 97.66 25 64.25 27 69.39 28 71.96
Full blood 
count




3.90 15 58.50 12 46.80 10 39.00 8 31.20
CSF analysis 18.28 3 54.84 4 73.12 6 109.68 4 73.12
Chest x-ray 8.97 1 8.97 1 8.97 0 0 1 8.97
Total cost per 
group
635.25 620.74 798.87 726.85










Table 9 Quantity and cost of hospitalisation in USD by treatment alternatives








No of days Cost No of days Cost No of days Cost No of days Cost
Admission fees 2.50 59 147.5 68 170 77 192.5 67 167.5
Mean number of days per patient 1.97 2.43 2.57 2.23
Range 0–4 1–5 2–5 0–4









No of units Cost No of units Cost No of units Cost No of units Cost
Nursing care time per day 2.49 59 146.91 68 169.32 77 191.73 67 166.83
Doctor consultation per visit—GP 1.00 12 12.00 13 13.00 15 15.00 14 14
Doctor consultation per visit—paediatrician 3.23 18 58.14 15 48.45 15 48.45 16 51.68
Total cost 217.05 230.77 255.18 232.51











Treatment alternative Cost ($) Effect (PRR24) Incremental cost ($) Incremental effect (PRR24) ICER ($ per PRR24) Comment
QLD 51.45 0.8384 Baseline (B)
QNLD2 52.88 0.7987 1.43 −0.0397 36.020 Extended dominated
ARTES 57.85 0.9752 4.97 0.1765 28.159 Comparator (A)
QNLD3 58.18 0.7543 0.33 Dominated
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quinine was diluted in dextrose. Lower quantities and 
costs of dextrose and electrolyte solutions for the ARTES 
group were recorded compared to any of the quinine 
groups. This observation is similar to that of Lubell et al. 
[10] who estimated cost of fluids at US$ 12.5 for artesu-
nate as compared to US$ 13.5 for quinine. However, it 
is important to note that a keep-vein-open is not com-
pulsory for the treatment with artesunate. Patients who 
might not need an IV line can just have an indwelling 
catheter, through which artesunate will be administered 
as a bolus.
In this study, the cost of all the thick blood films done 
(3–15 per patient) was included in the cost of laboratory 
investigations though practically, this is usually deter-
mined only once on admission. With this consideration, 
the overall cost of laboratory investigations was lower 
for artesunate-treated patients than for quinine-treated 
patients. The difference observed in our study is prin-
cipally because fewer thick blood films were done for 
artesunate-treated patients as a result of the rapid para-
site clearance time associated with this drug and quick 
clinical recovery. Whereas including only one thick blood 
film in the estimates (as this will be practically done), the 
mean cost for laboratory investigations falls to 13.3 USD 
for ARTES group, 12.2 USD for QLD group, 12.1 USD 
for QNLD3 group and 10.6 USD for QNLD2 group. The 
mean cost is higher in the ARTES group because in the 
course of randomisation this group found itself with the 
highest number of patients with severe anaemia and a 
control haematocrit level was done to these patients on 
day 3.
The mean cost of hospitalization per patient was signif-
icantly lower for patients in the ARTES group than in the 
other groups. This difference can be explained by the fact 
that clinical recovery, parasite negation and hence dura-
tion of hospitalization was lower for artesunate-treated 
patients than for quinine-treated patients.
Cost of professional fees was calculated based on cost 
of nursing care per day, cost of doctor consultation for 
the GP and for the paediatrician. Cost of professional 
fees was highest in the QNLD3 group and the lowest cost 
was recorded in the ARTES group. This is due to the fact 
that administration of artesunate requires less nursing 
care and does not require any monitoring as compared to 
quinine, which requires monitoring of a rate-controlled 
infusion and thus nursing care is costlier. Moreover, clini-
cal and parasitological recovery was longer for patients in 
the QNLD3 group, thus requiring more nursing care.
Overall, treatment of severe malaria with artesunate 
had higher costs, but the difference was not statistically 
significant. Lubell et  al. [10] obtained a similar result 
when comparing artesunate with the quinine loading 
dose regimen. As stated above, the overall cost of case 
management of severe malaria in this study included 
the cost of all the thick blood films done. Considering 
that this is usually done once on admission, the practi-
cal cost of treating severe malaria in this setting could 
be estimated at 50.01 USD for the ARTES group, 44.14 
USD for the QLD group, 43.4 USD for QNLD3 group 
and 39.4 USD for QNLD2 group. Probabilistic modelling 
using the decision tree yielded expected cost of $63.18 in 
ARTES compared to $50.91 in QNLD2; however, ARTES 
recorded the lowest cost/effect because of the higher 
expected effect of 0.89 compared to 0.695 in QNLD2 
(Fig. 2; Table 12).
This cost can be related to the average standard of 
living in Cameroon. According to the 3rd Cameroon 
household survey in 2007, the standard of living of Cam-
eroonians was estimated at 37.3 USD/head/month [19]. 
Hence, it can be inferred that treatment of malaria with 
artesunate at $65.14 is expensive because it costs more 
than the estimated monthly total expenditure; thus the 
need for treatment subsidy. It should be noted that the 
Cameroon government has subsidized malaria treatment 
in children less than 5 years old. In this age category and 
for pregnant women, treatment of severe malaria is free 
of charge [20, 21]. However, treatment of severe malaria 
remains expensive for the rest of the population. Moreo-
ver, this government subsidy only covers anti-malarials, 
dextrose solutions and nursing care materials; adjuvant 
treatment is not included. As shown in the results, adju-
vant treatment considerably increased the cost of severe 
malaria (34.1% of the total cost). Thus subsidies can also 
target adjuvant treatment. The cost of ARTES can also be 
related to the decision threshold or maximum amount 
that policymakers are willing to spend to avert for an 
additional unit of effectiveness, usually expressed in life 
years (LY) or disability adjusted life years (DALY), esti-
mated at $25 by the WHO. The measure of effectiveness 
was not LY or DALY but rather PRR24 from which was 
calculated the incremental cost per PRR24, making it dif-
ficult to compare the obtained ICER with existing deci-
sion thresholds.
Limitations
The societal perspective of economic evaluation offers 
the most comprehensive framework for analysis but 
the study was conducted from a healthcare perspective 
because of the absence of benchmark productivity data. 
Furthermore, there are several methodological limita-
tions relating to the choice of PRR24 over preference 
based measures such as QALY and DALY; inability to 
include fixed hospital costs in the analysis as well as the 
use of modelling and sensitivity analysis.
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Conclusion
The 3rd United Nations Sustainable Development Goals 
target to achieve access to qualitative healthcare ser-
vices and access to safe, effective and affordable essential 
medicines on the platform of financial risk protection or 
universal health coverage can be undermined by lack of 
access to affordable malaria treatment.
The decision to adopt a drug of choice for severe 
malaria should, therefore, be based not only on clinical 
effectiveness, but also its effect on health budgets for 
individuals, households and governments. This study 
revealed that although artesunate is costlier than the qui-
nine alternatives, it is more effective in terms of PRR24 































































Fig. 2 Probabilistic decision modeling for treatment options
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that artesunate is the most cost-effective of all treatment 
alternatives examined with an ICER of $46.78 relative to 
QLD. Nonetheless it remains expensive as relative to the 
standard of living of Cameroonians where most people 
live on an estimated $37 per month. Adoption of artesu-
nate is best considered alongside some form of financial 
protection in the form of insurance schemes or treatment 
subsidies especially subsidies targeted at the cost of the 
artesunate and adjuvant therapy.
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